An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ReViral Appoints Brett Haumann as Chief Medical Officer
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
ReViral Ltd. announces the appointment of Dr. Brett Haumann as Chief Medical Officer, responsible for global clinical development and regulatory strategy. Dr. Haumann has a proven track record in respiratory and infectious diseases, including leadership roles at Theravance Biopharma and GlaxoSmithKline. His expertise will support the development of ReViral's lead candidate, sisunatovir, currently in phase 2 studies for RSV infections in infants. ReViral is focused on antiviral therapeutics and aims to address the substantial global disease burden posed by RSV.
Positive
Appointment of Dr. Brett Haumann enhances leadership with extensive experience in respiratory drug development.
Dr. Haumann's expertise is expected to advance the clinical development of sisunatovir.
Negative
None.
LONDON & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
ReViral Ltd. today announced that Brett Haumann, MD, has joined the company as Chief Medical Officer. Dr. Haumann will be responsible for the company’s global clinical development and regulatory strategy as its lead candidate, sisunatovir, continues its progress through a phase 2 study in infants hospitalized with respiratory syncytial virus (RSV) respiratory tract infections.
“I am delighted to welcome Brett, a seasoned and highly respected clinician and leader, to ReViral,” said Alex C. Sapir, ReViral’s Chief Executive Officer. “Throughout his career, Brett has built a reputation as an outstanding leader among industry and medical communities in the US and Europe alike. Brett’s respiratory background and experience in combination drug development make him the ideal addition to the ReViral leadership team. I look forward to him applying that expertise to the further development of sisunatovir and our N-protein replication inhibitor program.”
Dr. Haumann joins ReViral after spending the past seven years as Chief Medical Officer and Senior Vice President of Development at Theravance Biopharma. During his tenure, he led a multi-functional organization developing a broad portfolio of novel assets in multiple therapeutic areas including respiratory and infectious diseases. He spent time in both European and US subsidiaries of the company and oversaw the successful development and first-cycle FDA approval of revefenacin (YUPELRI®) for the treatment of COPD. Before Theravance, Dr. Haumann spent more than 15 years in senior development roles at GlaxoSmithKline (GSK), including as Vice President of Clinical Development, where he served as the global Medicines Development Leader, leading the successful development and approval of RELVAR®/BREO® for the treatment of asthma and COPD. Dr. Haumann has also served as a non-executive director on a number of private and public boards in Europe and the US, including most recently as the Head of the R&D Committee on the Board of Aimmune Therapeutics, prior to its acquisition by Nestlé in 2020. Dr. Haumann holds an M.D. from Witwatersrand University in South Africa and an MBA from The Open University in the UK.
Dr. Haumann said: “I’m honored to have the opportunity to lead ReViral’s clinical development program at such an important moment in its evolution. I am looking forward to working with the company’s talented team to build a robust pipeline that has the potential to transform the care of RSV patients around the world.”
Notes to Editors
About ReViral
ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on treating respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, an orally administered fusion inhibitor granted Fast Track designation by the U.S. Food and Drug Administration (FDA), is currently in phase 2 clinical studies in a pediatric patient population. The company also has an RSV N-protein replication inhibitor program undergoing IND enabling studies. In 2021, ReViral announced a multimillion-dollar licensing deal with LianBio to develop and commercialize sisunatovir in mainland China, Hong Kong, Macau, and Singapore.
About Respiratory Syncytial Virus (RSV)
RSV is a respiratory pathogen that can lead to severe and life-threatening lower respiratory tract infections (LRTIs) in high-risk populations, such as infants, immunocompromised patients, and the elderly. Thus, RSV constitutes a substantial disease burden. The US-Based National Institute of Health (NIH) estimates that RSV affects approximately 64 million people and causes approximately 160,000 deaths globally each year. In addition, there are an estimated 33 million global cases of RSV LRTI each year in children younger than five years of age, with around 3 million hospitalized and approximately 60,000 dying from complications associated with the infection. There are no effective therapeutic treatment options for patients who develop RSV infection.
Who is the new Chief Medical Officer of ReViral and what is his background?
Dr. Brett Haumann is the new Chief Medical Officer of ReViral. He has extensive experience in clinical development, having previously worked as CMO at Theravance Biopharma and held senior roles at GlaxoSmithKline, leading significant drug approvals.
What is the main responsibility of Dr. Haumann at ReViral?
Dr. Haumann will lead global clinical development and regulatory strategy, focusing on the company's lead candidate, sisunatovir, in phase 2 studies for respiratory syncytial virus (RSV).
What is sisunatovir and its significance in the drug development pipeline of ReViral?
Sisunatovir is ReViral's lead product candidate, a fusion inhibitor currently undergoing phase 2 studies aimed at treating RSV infections, which pose a significant health burden globally.
What prior experience does Dr. Haumann bring to ReViral?
Dr. Haumann has over 15 years of experience in drug development, including leading the successful development and FDA approval of treatments for respiratory diseases.
How does ReViral plan to address the global impact of RSV?
ReViral aims to develop effective antiviral therapeutics like sisunatovir to mitigate the severe health impacts of RSV, which affects millions worldwide.
